Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 10/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28540140 | 0.85 | MAOB (0.58) | IDO1MAOBNR4A2PPARDPPARA | |
| SCHEMBL3321627 | 0.85 | MAOB (0.68) | IDO1MAOBNR4A2MRGPRX4FFAR1 | |
| SCHEMBL697164 | 0.84 | MAOB (0.65) | IDO1MAOBMRGPRX4FFAR1 | |
| SCHEMBL12424195 | 0.81 | MAOB (0.54) | IDO1MAOBNR4A2 | |
| SCHEMBL12584946 | 0.79 | MAOB (0.53) | IDO1MAOBNR4A2PPARDPPARA | |
| SCHEMBL13960103 | 0.78 | MAOB (0.54) | IDO1MAOBNR4A2FFAR1FFAR4 | |
| SCHEMBL863820 | 0.77 | GSK3B (0.49) | IDO1MAOBNR4A2 | |
| SCHEMBL6690271 | 0.76 | RAB9A (0.54) | IDO1MAOBNR4A2PPARDPPARA | |
| SCHEMBL21944825 | 0.75 | IDO1 (0.53) | IDO1MAOBNR4A2PPARDPPARA | |
| SCHEMBL697659 | 0.74 | FFAR1 (0.50) | MAOBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689771-B2 | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |